Brand Name
Sensipar
Generic Name
Cinacalcet
View Brand Information FDA approval date: April 04, 2004
Classification: Calcium-sensing Receptor Agonist
Form: Tablet
What is Sensipar (Cinacalcet)?
Sensipar is a positive modulator of the calcium sensing receptor indicated for: Secondary Hyperparathyroidism in adult patients with chronic kidney disease on dialysis.
Approved To Treat
Top Global Experts
Save this treatment for later
Not sure about your diagnosis?
Related Clinical Trials
A Multicenter, Randomized, Double-blind, Double-dummy, Phase III Study to Evaluate the Efficacy and Safety of MT1013 Versus Cinacalcet as Active Control in Secondary Hyperparathyroidism Patients on Maintenance Dialysis
Summary: MT1013 is a first-in-class dual-target agonist. This study is a multicenter, randomized, double-blind, double-dummy phase III clinical study being conducetd to evaluate the efficacy and safety of MT1013 compared with active control cinacalcet in secondary hyperparathyroidism patients on maintenance dialysis. Subjects will be 1:1 randomized to receive MT1013 or cinacalcet for 26 weeks. Evaluations ...